je.st
news
Tag: drug
Cancer research UK launches trial for potential new drug that could help immune system fight cancer
2016-02-24 12:41:14| Biotech - Topix.net
Cancer Research UK's Centre for Drug Development , in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours. Cancer Research UK scientists are studying Amgen's experimental cancer drug, called AMG319, to find out if it removes the defence shield that hides cancer cells from the immune system.
Tags: system
research
potential
trial
Earnings Results: Fresh Del Monte earnings hurt by banana surplus, drug trade
2016-02-23 22:54:59| Agriculture - Topix.net
Fresh Del Monte Produce Inc. said an oversupply of bananas and the use of banana ships in the global drug trade were a drag on quarterly earnings, despite gains made in the growing avocado business. shares closed down 4.9% at $38.52 on Tuesday after it reported a loss of $1.39 per share, up from a penny per share the year before.
UPDATE 1-UK cost agency queries value of $700,000-a-year Alexion drug
2016-02-18 12:56:58| Biotech - Topix.net
An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said. Kanuma is designed for treating lysosomal acid lipase deficiency, a rare inherited genetic disease in which fats build up in cells.
Tarix Granted Orphan Drug Status For TXA127
2016-02-18 02:28:07| drugdiscoveryonline News Articles
Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127, for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-onset LAMA2-related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between 30 and 40 percent of total cases of congenital muscular dystrophy.
Tags: status
drug
granted
orphan
Crown Bioscience To Commercialize University Of York's Prostate Cancer Models For Drug Development
2016-02-17 02:07:05| drugdiscoveryonline News Articles
Crown Bioscience Inc., a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has reached an agreement with UK’s University of York to exclusively license and commercialize the university’s unique collection of patient-derived xenograft (PDX) models for prostate cancer.
Tags: development
university
models
drug
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] next »